scholarly journals Applying Feasibility Investigation of Resin Modifying Agent in Asphalt Pavement Materials

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Lijing Chu ◽  
Yi Li ◽  
Linghui Huang ◽  
Jingyu Qiu ◽  
Xiaolong Sun ◽  
...  

In order to promote the resin modifying agent applied into pavement materials, a type of resin modifying agent was selected as the modifier to prepare modified asphalt. The molecular crystal structure of the modifying material was characterized by using the X-ray diffraction test (XRD). The microstructure and element composition of PA6 was investigated through focused ion beam scanning electron microscopy (FIB-SEM). The thermal property and functional groups of PA6 were studied by thermogravimetric analysis-Fourier infrared spectroscopy (TG-FTIR) test. The physical property and rheological properties of PA modified asphalt were evaluated to confirm the applying feasibility of PA6 in asphalt. The results indicated that PA6 was the semicrystalline polymer and the existence of γ crystal form might improve the toughness of asphalt materials effectively. The thermal decomposition process of PA6 could be divided into three stages roughly: inert weight loss stage, rapid weight loss stage, and stable stage. The amount of PA6 modifier should be appropriately controlled during the application process to ensure the comprehensive effect of PA6 on high-temperature performance and low-temperature performance. The corresponding initial modulus attenuation value of PA modified asphalt was less than 70# asphalt under the same test conditions.

2013 ◽  
Vol 477-478 ◽  
pp. 1175-1178
Author(s):  
Ling Zou ◽  
Jing Wei Ne ◽  
Weng Gang Zhang

70# and 90# matrix asphalt mixture with MaR were studied through dynamic modulus test, rutting test, freeze-thaw splitting test, bending test to study the applicability of the Modifying agent of rubber plastic compound (MaR) in matrix asphalt mixture.Test results were Compared with SBSI-C modified asphalt mixture.The results indicate that: high-temperature stability of MaR+70# asphalt mixture is as well as SBSI-C modified asphalt mixture,and is bettere than MaR+90# asphalt mixture; water stability of MaR+90# asphalt mixture is bettere than SBSI-C modified asphalt mixture and MaR+70# asphalt mixture; low temperature performance of MaR+90# asphalt mixture is bettere than MaR+70# asphalt mixture, but is worse than modified asphalt mixture SBSI-C ; MaR+70# asphalt mixture can be first used in area of resisting high temperature and rutting, MaR+90# asphalt mixture can be used if the water stability performance and low temperature performance are considered.


2014 ◽  
Vol 1079-1080 ◽  
pp. 152-155
Author(s):  
Yuan Yuan Wang ◽  
Lu Sun

Using the waste pavement materials can not only save resources such as bitumen and aggregate, but also reduce the pollution of environment. In this study, the high temperature performance and the moisture stability of recycled SBS modified asphalt mixture were evaluated by rutting test, immersion Marshall Test and freeze-thaw splitting routine test. In addition, the low temperature performance of recycled modified mixture was also analyzed by Fénix test whose operation was simple. The tests results illustrated that it was advantageous to improve the high temperature performance of recycled mixture and it has less influence on moisture stability with the addition of RAP. However, it had a significant adverse effect on the low temperature performance for recycled SBS modified asphalt mixture with a large quantity of RAP content. Therefore, it suggests that the RAP content for recycled SBS modified mixture is not too high.


Diabetologia ◽  
2021 ◽  
Author(s):  
Wilma S. Leslie ◽  
Eman Ali ◽  
Leanne Harris ◽  
C. Martina Messow ◽  
Naomi T. Brosnahan ◽  
...  

Abstract Aims/hypothesis Our aim was to evaluate the safety and efficacy of a planned therapeutic withdrawal of all antihypertensive and diuretic medications, on commencing a formula low-energy diet replacement, targeting remission of type 2 diabetes. Methods Post hoc analysis of changes in BP, antihypertensive medication prescriptions and symptoms during the initial total diet replacement phase was performed in the intervention arm of the Diabetes Remission Clinical Trial (n = 143) and in the subset (n = 69) who discontinued antihypertensive medications at the start of total diet replacement. The Counterweight-Plus total diet replacement provided about 3470 kJ/day (830 kcal) with automatic reductions in all nutrients, including sodium, to achieve marked negative energy balance and rapid weight loss over 12–20 weeks, with regular BP monitoring and an antihypertensive reintroduction protocol based on current clinical guidelines. Results Of 143 intervention group participants who commenced total diet replacement, 78 (55%) were on treatment for hypertension at baseline. The overall mean BP fell significantly from the start of total diet replacement (week 1) and was significantly lower at week 20, after total diet replacement finished, and also at 12 and 24 months. Of the 78 participants previously on treatment for hypertension, 65 (83%) stopped all antihypertensive and diuretic medications as per protocol, and four (5%) stopped some drugs. These 69 participants experienced no immediate (within the first week) change in BP, but their mean BP fell significantly from 9 weeks. No excessive rises in BP were recorded in individuals, but antihypertensive medications were reintroduced during total diet replacement to manage raised BP for 19/69 (27.5%) participants, mostly within the first 3–7 weeks, despite some weight loss. Reintroduction of antihypertensive medications was necessary for 5/19 participants previously on one drug, and for 14/19 previously on two or more drugs. Of the 69 who stopped antihypertensives, 19 (28%) remained off medications at 24 months. Among the 53 participants who achieved sustained remissions of diabetes at 24 months (with a mean weight loss of 11.4 kg), 31 had been previously treated for hypertension. Twenty-seven stopped medication at baseline, and 15/27 required reintroduction of antihypertensive medications. Mild to moderate dizziness, suggesting some postural hypotension, was reported during total diet replacement by 51 participants, 15 of whom had recorded dizziness at baseline prior to starting total diet replacement, with nine of these on antihypertensive or diuretic medications. Conclusions/interpretation Replacing antihypertensive medications with a 3470 kJ/day (830 kcal) diet to induce weight loss reduces BP substantially and may increase mild dizziness. It is safe to stop antihypertensives, but BP should be monitored regularly, particularly for those taking two or more antihypertensives, as over two-thirds will require reintroduction of some medications. Long-term support to maintain weight loss is vital. Trial registration ISRCTN registry, number 03267836. Graphical abstract


2007 ◽  
Vol 56 (4) ◽  
pp. 429-436 ◽  
Author(s):  
TAKESHI KUKIDOME ◽  
KATSUJI AIZAWA ◽  
AI OKADA ◽  
KUMPEI TOKUYAMA ◽  
ICHIRO KONO

2010 ◽  
pp. P2-237-P2-237
Author(s):  
A Chandrasekhar ◽  
M Schaefer ◽  
G Gopalakrishnan

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 79
Author(s):  
Mikiko Watanabe ◽  
Angela Balena ◽  
Davide Masi ◽  
Rossella Tozzi ◽  
Renata Risi ◽  
...  

Obesity is associated with a poor COVID-19 prognosis, and it seems associated with reduced humoral response to vaccination. Public health campaigns have advocated for weight loss in subjects with obesity, hoping to eliminate this risk. However, no evidence proves that weight loss leads to a better prognosis or a stronger immune response to vaccination. We aimed to investigate the impact of rapid weight loss on the adaptive immune response in subjects with morbid obesity. Twenty-one patients followed a hypocaloric, very-low-carbohydrate diet one week before to one week after the two mRNA vaccine doses. The diet’s safety and efficacy were assessed, and the adaptive humoral (anti-SARS CoV-2 S antibodies, Abs) and cell-mediated responses (IFNγ secretion on stimulation with two different SARS CoV-2 peptide mixes, IFNγ-1 and IFNγ-2) were evaluated. The patients lost ~10% of their body weight with metabolic improvement. A high baseline BMI correlated with a poor immune response (R −0.558, p = 0.013 for IFNγ-1; R −0.581, p = 0.009 for IFNγ-2; R −0.512, p = 0.018 for Abs). Furthermore, there was a correlation between weight loss and higher IFNγ-2 (R 0.471, p = 0.042), and between blood glucose reduction and higher IFNγ-1 (R 0.534, p = 0.019), maintained after weight loss and waist circumference reduction adjustment. Urate reduction correlated with higher Abs (R 0.552, p = 0.033). In conclusion, obesity is associated with a reduced adaptive response to a COVID-19 mRNA vaccine, and weight loss and metabolic improvement may reverse the effect.


2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
Emi Kondo ◽  
Keiko Motonaga ◽  
Satoko Ozawa ◽  
Yoshiko Ishii ◽  
Akiko Sato ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document